Use of Non-GAAP Measures
In addition to disclosing financial results calculated in accordance with generally accepted accounting principles in conformity with International Financial Reporting Standards (GAAP), this press release contains Non-GAAP financial measures for gross profit, operating expenses, operating profit (loss), net income (loss) and basic and diluted earnings (loss) per share that exclude the effects of non-cash expense of amortization of intangible assets and share-based payments and costs related to the merger agreement. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance that enhances management's and investors' ability to evaluate the Company's net income (loss) and earnings (loss) per share and to compare them to historical net income (loss) and earnings (loss) per share.
The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company's business internally and therefore decided to make these non-GAAP adjustments available to investors.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance System enables surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the closing of the Medtronic acquisition of Mazor, statements regarding the benefits of the Mazor X–Stealth Edition system, and other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC) including those discussed under the heading "Risk Factors" in Mazor's annual report on Form 20-F filed with the SEC on April 30, 2018 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
Mazor Robotics Ltd. | ||||||||||||||||
CONSOLIDATED STATEMENT OF PROFIT OR LOSS | ||||||||||||||||
(U.S. Dollars in thousands, except per share data) | ||||||||||||||||
(UNAUDITED) | ||||||||||||||||
| ||||||||||||||||
|
|
| Nine months period |
|
| Three months period | ||||||||||
|
|
| ended September 30, |
|
| ended September 30, | ||||||||||
|
|
| 2018 |
|
| 2017 |
|
| 2018 |
|
| 2017 | ||||
Revenue |
|
| $ | 38,835 |
|
| $ | 45,798 |
|
| $ | 10,090 |
|
| $ | 18,624 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
| $ | 17,587 |
|
| $ | 15,895 |
|
| $ | 5,315 |
|
| $ | 7,020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
| $ | 21,248 |
|
| $ | 29,903 |
|
| $ | 4,775 |
|
| $ | 11,604 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development,
|
|
| $ | 8,695 |
|
| $ | 5,692 |
|
| $ | 3,626 |
|
| $ | 1,658 |
Selling and marketing |
|
| $ | 17,944 |
|
| $ | 32,638 |
|
| $ | 5,656 |
|
| $ | 12,429 |
General and administrative |
|
| $ | 6,618 |
|
| $ | 5,310 |
|
| $ | 2,176 |
|
| $ | 1,653 |
Other operating expenses (*) |
|
| $ | 10,800 |
|
| $ | - |
|
| $ | 10,800 |
|
| $ | - |
Total operating cost and
|
|
| $ | 44,057 |
|
| $ | 43,640 |
|
| $ | 22,258 |
|
| $ | 15,740 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
| $ | (22,809) |
|
| $ | (13,737) |
|
| $ | (17,483) |
|
| $ | (4,136) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing income, net |
|
| $ | 750 |
|
| $ | 631 |
|
| $ | 541 |
|
| $ | 188 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before taxes on
|
|
| $ | (22,059) |
|
| $ | (13,106) |
|
| $ | (16,942) |
|
| $ | (3,948) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
| $ | 2 |
|
| $ | (250) |
|
| $ | 1 |
|
| $ | - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
| $ | (22,061) |
|
| $ | (12,856) |
|
| $ | (16,943) |
|
| $ | (3,948) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share - Basic
|
|
| $ | (0.42) |
|
| $ | (0.27) |
|
| $ | (0.32) |
|
| $ | (0.08) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common
|
|
|
| 52,673 |
|
|
| 48,334 |
|
|
| 52,938 |
|
|
| 49,011 |
| ||||||||||||||||
(*) Merger agreement related expenses |